20Jul 2022
Phase II Proof of Concept Study of Atorvastatin in Castration Resistant Prostate Cancer

Phase II Proof of Concept Study of Atorvastatin in Castration Resistant Prostate Cancer

To test for evidence of statin‐mediated effects in patients with castration-resistant prostate cancer, post-diagnosis use of statins in patients with prostate cancer is associated with favourable survival outcomes. In addition, enhanced tumoral cholesterol uptake can drive castration-resistant prostate cancer (CRPC). At the scheduled interim analysis, one of twelve patients experienced a ≥50% drop in PSA levels (primary endpoint), with ≥2 patients satisfying the primary endpoint required for further recruitment. Data from the SPECTRE study provides the first evidence of statin-mediated effects on CRPC and early signs of disease stabilisation. The data also highlights the possibility of altered tryptophan metabolism associated with tumour response.

  • #urology

Like

Save

Share